Could CGM Help People With Type 1 Diabetes Live Longer?

Could continuous glucose monitoring do more than improve glucose levels and help prevent hypoglycemia? New research raises that possibility. A large observational study examining CGM use and mortality in people with type 1 diabetes found that starting continuous glucose monitoring was associated with a lower risk of death among older adults with the condition. However, the results do not prove that CGM itself extends life. Instead, they provide an important reason to investigate whether the benefits of real-time glucose information may eventually translate into better long-term outcomes.

Table of Contents

• What the study found about CGM and mortality
• Why CGM might be linked with lower mortality
• Which people with type 1 diabetes were studied
• Why the findings do not prove CGM extends life
• Conclusion
• Frequently Asked Questions

What the Study Found About CGM and Mortality in Type 1 Diabetes

Researchers analyzed Veterans Health Administration records using a method called target trial emulation. This approach uses observational data while trying to reproduce some features of a randomized clinical trial. The study included 8,423 adults with type 1 diabetes who met the researchers’ eligibility criteria.

Among them, 1,039 were prescribed CGM during the study’s initial treatment-assignment period. Researchers then compared mortality outcomes associated with starting CGM versus not starting it.

The results were notable. Adjusted mortality risk ratios ranged from 0.90 after one year to 0.84 after approximately four years. In other words, CGM initiation was associated with a progressively lower relative risk of all-cause mortality during follow-up. By year four, the absolute difference in mortality risk between the groups was about two percentage points.

Importantly, the association remained similar when researchers changed the period allowed for CGM initiation from six months to either three or nine months. Additional adjustments for factors such as age and frailty also did not substantially change the findings.

The study therefore adds a potentially important dimension to the growing evidence surrounding continuous glucose monitoring. CGM has already demonstrated benefits for glucose management. However, whether those improvements ultimately translate into longer life has remained much less certain.

Why Continuous Glucose Monitoring Might Affect Long-Term Risk

There are several plausible reasons CGM could be associated with better outcomes. First, continuous monitoring gives people far more information about glucose patterns than periodic finger-stick measurements alone. Users can see whether glucose is rising, falling, or remaining stable and may receive alerts when levels move outside their target range.

As a result, people may be able to respond earlier to dangerous glucose changes. That matters because severe hypoglycemia and extreme hyperglycemia can lead to emergency treatment, hospitalization, and other serious complications.

CGM may also help patients and clinicians identify patterns that an A1C test cannot show. A1C provides an estimate of average glucose over several months, but averages can hide large swings between high and low glucose.

Indeed, separate real-world research has found that CGM measures such as time in range, glucose variability, and time above range were associated with all-cause mortality even after accounting for A1C. That does not establish causation either. Nevertheless, it suggests that the information captured by CGM may reveal aspects of glucose exposure relevant to long-term health.

In the new study, CGM initiation was also associated with a greater decline in A1C during follow-up. Still, improved A1C alone may not explain the observed mortality difference. More research is needed to determine whether fewer acute glucose events, reduced variability, better treatment decisions, or other factors could contribute.

Which People With Type 1 Diabetes Were Represented?

The population studied is critical when interpreting the findings. Participants came from the Veterans Health Administration and represented adults with older-onset type 1 diabetes receiving specialty endocrine care.

The researchers reported that people older than 65 and those who were not using insulin pumps appeared to experience greater benefit. However, the estimated effect did not meaningfully differ according to baseline A1C, race or ethnicity, or frailty.

Among participants who were not using an insulin pump at baseline, CGM use was associated with lower risks for several outcomes, including hospitalization, hypoglycemia, combined hypo- and hyperglycemia-related admissions, and cardiovascular events.

Those findings offer possible clues about how continuous glucose monitoring could influence health outcomes. However, subgroup findings require cautious interpretation and should not automatically be applied to every person with type 1 diabetes.

The VA population also differs from the overall type 1 diabetes population. Therefore, results may not translate directly to younger adults, people diagnosed during childhood, or populations with different demographic and clinical characteristics.

For people considering CGM or changes to diabetes treatment, individual circumstances remain important. A diabetes specialist or other qualified healthcare professional can help determine which monitoring approach fits a patient’s needs.

Why This Research Cannot Prove CGM Extends Life

The most important limitation is simple: association is not causation.

Researchers used a sophisticated target trial emulation design to reduce several biases common in observational studies. For example, statistical methods attempted to balance factors that could influence whether someone started CGM. The investigators also examined health outcomes that would not be expected to improve because of CGM as negative controls.

Those methods strengthen the analysis. However, they cannot eliminate every possible difference between people who start CGM and those who do not.

CGM users might differ in healthcare engagement, access to technology, diabetes education, treatment adherence, socioeconomic factors, or other characteristics that are difficult to measure completely. Any of these differences could influence survival independently of the device.

Furthermore, the study did not randomly assign participants to CGM or no CGM. A randomized controlled trial designed around major clinical outcomes would provide stronger evidence about whether CGM itself reduces mortality.

For now, the most accurate interpretation is that CGM initiation was associated with lower mortality in this particular population. The study raises an important hypothesis rather than providing definitive proof that CGM makes people live longer.

Conclusion

The latest evidence on CGM use and mortality in type 1 diabetes points toward an intriguing possibility. Continuous glucose monitoring may have benefits that extend beyond better A1C, more time in range, and fewer dangerous glucose excursions.

In this large Veterans Health Administration analysis, people who started CGM had lower all-cause mortality during up to four years of follow-up. The association was particularly interesting among older adults and people who were not already using insulin pumps.

Still, observational evidence cannot establish that CGM caused the reduction in mortality. Future studies will need to determine whether the association is reproducible in broader populations and identify the mechanisms that might explain it.

For clinicians and patients, the findings strengthen the case for looking beyond A1C when evaluating diabetes technology. They also open a larger question for future research: could better real-time glucose information eventually translate into longer, healthier lives?

Frequently Asked Questions

Does CGM reduce mortality in people with type 1 diabetes?

A recent observational study found that CGM initiation was associated with lower all-cause mortality among older adults with type 1 diabetes. However, the study cannot prove that CGM directly caused the reduction.

How large was the mortality difference?

Adjusted mortality risk ratios ranged from 0.90 after one year to 0.84 after roughly four years. By four years, researchers reported an absolute mortality risk difference of approximately two percentage points.

Why could CGM potentially improve long-term outcomes?

CGM provides real-time glucose trends and alerts that may help people recognize and treat high or low glucose sooner. It can also reveal glucose variability and time-in-range patterns that A1C alone cannot capture.

Were the findings stronger in certain patients?

People older than 65 and those who were not using insulin pumps appeared to have greater benefit. However, subgroup findings should be interpreted carefully and require confirmation in additional research.

Does this study mean everyone with type 1 diabetes should start CGM to live longer?

No. The research found an association rather than proof of a survival benefit. Decisions about CGM should consider individual glucose-management needs, preferences, access, and guidance from a qualified healthcare professional.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.